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1. Introduction 
Antidepressants that block the reuptake of serotonin (5-HT) and noradrenaline (NA) are 
called 5-HT and NA reuptake inhibitors (SNRIs). SNRIs are agents that show “dual 
action” on 5-HT and NA. These drugs bind the 5-HT transporters (SERT) and NA 
transporters (NAT) similar to tricyclic antidepressants (TCAs). However, SNRIs differ 
from TCAs in that SNRIs do not exert much affinity for other receptors. Altough SNRIs 
are called “dual action” 5-HT - NA agents they increase dopamine levels in the prefrontal 
cortex via NAT inhibition. In this way, they have a third action on neurotransmitters in 
the prefrontal cortex.  
The main use of SNRIs is in the treatment of major depression. Other applications include 
treatment of pain disorders (including neuropathies and fibromyalgia), generalized anxiety, 
vasomotor symptoms of menopause and stress urinary incontinence (Susman N, 2003). The 
class of SNRIs now comprises five medications: venlafaxine (Effexor XR, Efexot XR), its 
metabolite desvenlafaxine (Pristique), milnacipran (Ixel, Toledomin), duloxetine (Cymbalta, 
Xeristar) and mirtazapine (Remeron). 
1. Venlafaxine XR (Effexor) 
25, 37.5,50, 75,100 mg tablets; 37.5,75,150 mg extended release capsules  
2. Desvenlafaxine (Pristique) 
50, 100 mg capsules 
3. Milnacipran (Ixel, Toledomin) 
100 mg/day (given as 50 mg 2 times daily,  
with a starting period of 4 days on 25 mg/day). 
4. Duloxetine (Cymbalta) 
20, 30, 50 mg capsules 
5. Mirtazapine (Remeron) 
15 mg to 45 mg/day 
Table 1. Serotonin norepinephrine reuptake inhibitors (SNRIs) 
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2. Pharmacology 
2.1 Pharmacodynamics 
SNRIs bind to 5-HT and NA transporters to selectively inhibit the reuptake of these 
neurotransmitters from the synaptic clefts. They have a “dual mode of action”. SNRIs block 
the reuptake of both 5-HT and NA with differing selectivity. Whereas milnacipran blocks 5-
HT and NA reuptake with equal affinity, duloxetine has a 10-fold greater selectivity for 5-
HT, and venlafaxine has a 30-fold greater selectivity for 5-HT (Stahl et al., 2005). 
Venlafaxine was the first SNRI to be introduced. Venlafaxine inhibits neuronal uptake of 5-
HT (most potent, present at low doses), NA (moderate potency, present at high doses) and 
dopamine (DA) in order of decreasing potency. Venlafaxine has no affinity for ǂ2- or ǃ-
adrenoceptors, benzodiazepine or opiate receptors. It has a much greater affinity for the 5-
HT transporter than for the norepinephrine (NE)  transporter. At low doses, it inhibits the 5-
HT transporter almost exclusively, acting like a selective serotonin reuptake inhibitor (SSRI), 
with significant NE reuptake inhibition only occurring at higher doses (Saletu et al., 1992). 
Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine. The 
neurotransmitters affected by the drug are 5-HT and NE. It is approximately 10 times more 
potent at inhibiting 5-HT uptake than NE uptake. It has low affinity for other brain 
neurotransmitter targets, including muscarinic, cholinergic, histamine (H1) and ǂ-
adrenergic receptors (Whyte & Dawson, 2003; Septien-Velez et al., 2007). 
Previous studies demonstrated that duloxetine potently inhibits neuronal 5-HT and NE re-
uptake. It has been demonstrated that this inhibition is balanced throughout the dosing 
range compared to venlafaxine, which demonstrates low inhibition of NA at low doses and 
rises as the dose escalates. Duloxetine is also considered a less potent inhibitor of dopamine 
re-uptake. Duloxetine has no significant affinity for adrenergic, cholinergic, histaminergic, 
opioid, glutamate, or GABA receptors. It binds selectively with high affinity to both NA and 
5-HT transporters and lacks affinity for monoamine receptors within the central nervous 
system. Additionally, duloxetine is a more potent 5-HT reuptake inhibitor compared to 
fluoxetine (SSRI) (Westanmo & Gayken, 2005; Bymaster et al., 2001).  
Milnacipran is the most balanced SNRI, and some studies have even found it to be slightly 
more effective for the NE transporter compared with the 5-HT transporter. Milnacipran 
inhibits the re-uptake of 5-HT and NA in an approximate 1:3 ratio; in practical use, this 
means a relatively balanced action upon both neurotransmitters. Milnacipran shows 
antidepressive activity due to suppression of 5-HT re-uptake and NA in postsynaptic 
receptors. Milnacipran exerts no significant actions on H1, ǂ1, DA1, DA2, and mACh 
receptors or on benzodiazepine and opioid binding sites. The biochemical profile of 
milnacipran and its lack of interaction with other neurotransmitters indicate that the drug 
may be maximally effective in the treatment of depression while being free of the side-
effects associated with other antidepressants. Simultaneous inhibition of both 5-HT and NA 
works synergistically to treat both fibromyalgia and depression (Vaishnavi & Nemeroff, 
2004). 
Mirtazapine is a tetracyclic compound with antidepressant activity. It has a unique 
mechanism of action that is different from classical tricyclic antidepressants, the SSRIs and 
monoamine oxidase inhibitors. Therefore, it could be described as a noradrenergic and 
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specific serotonergic antidepressant. Mirtazapine’s pharmacological profile is characterized 
by a potent presynaptic alpha-2-adrenergic antagonist activity, 5-HT1 agonist activity, and 
potent 5-HT2 and 5-HT3 antagonist activities as well as by a potent H1 antagonistic activity. 
The blockade of presynaptic alpha-2-adrenergic receptors is considered as a possible 
mechanism for the antidepressant activity of mirtazapine. It is also a strong H1 receptor 
antagonist, therefore, it causes sedative side effects (Dekeyne & Millan, 2008; Millan et al., 
2000). 
    
Venlafaxine    Desvenlafaxine 
   
 Milnacipran     Duloxetine 
 
 
Mirtazapine 
Fig. 1. Structure of SNRI-class antidepressants 
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Fig. 2. The amin hypothesis of major depression. Depression appears to be associated with 
changes in serotonin and norepinephrine signaling in brain (or both) with significant 
downstream effects. Most antidepressants cause changes in amine signaling. AC, adenyly 
cyclase; 5-HT, serotonin; CREB, c AMP response element binding (protein); DAG, diacyl 
glycerol; IP3, inositol trisphosphate; MAO ( monoamine oxidase), NET (norepinephrine 
transporter), PKC: protein kinase C; PLC, phospholipase C; SERT, serotonin transporter 
(From: Katzung, B.G.; Masters, S.B.; Trevor, A.J. 11 th edition. Basic and clinical 
pharmacology. International edition). 
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Fig. 3. The serotonin synapse. Serotonin is synthesized from tryptophan by the enzyme 
tryptophan hydroxylase. Serotonin is then packaged into vesicles for release into the 
synaptic cleft, which occurs when there is sufficient stimulation of the neuron. Serotonin 
released from the serotonin neuron into the synaptic cleft has multiple actions. (1) Serotonin 
binds to its receptors on other neurons. Activation of postsynaptic receptors results in 
transduction of the signal that initially stimulated the serotonin neuron. (2) Serotonin also 
binds to presynaptic serotonin receptors on the neuron from which it was released, which 
provides feedback and regulates plasticity of the neuron. (3) Serotonin is taken up back into 
the presynaptic serotonin neuron by the serotonin transporter. Serotonin is then recycled for 
future release or broken down by monoamine oxidase and excreted in urine (From: aan het 
Rot, M., Mathew, S.J.; Charney, D.S. (2009). Neurobiological mechanisms in major 
depressive disorder. CMAJ. 3;180(3):305-13). 
2.2 Pharmacokinetics  
Venlafaxine is a bicyclic phenyetilamine derivative. The mean half-life of venlafaxine is 
approximately 4 h and is relatively short. Venlafaxine is well-absorbed from the 
gastrointestinal tract and is a substrate for CYP450. It is extensively metabolized in the liver 
via the CYP2D6 isoenzyme to desvenlafaxine (O-desmethylvenlafaxine), which is just as 
potent a 5-HT-NA reuptake inhibitor as the parent compound. This means that the 
www.intechopen.com
 
Effects of Antidepressants 
 
96
differences in the metabolism between extensive and poor metabolizers are not clinically 
important in terms of efficacy. Therapeutic effects are usually achieved within 3 to 4 weeks. 
The primary route of excretion of venlafaxine and its metabolites is via the kidneys 
(Wellington and Perry, 2001). Desvenlafaxine has linear pharmacokinetics, low protein 
binding, a half-life of approximately 10 h and is metabolized primarily via glucuronidation 
and to a minor extent, through CYP3A4. The desvenlafaxine succinate has a good oral 
bioavailability. Clearance rates are reduced in the elderly, those with severe renal 
dysfunction and those with moderate to severe hepatic dysfunction, each of which may 
require dosage adjustments. Desvenlafaxine is excreted in the urine, is minimally 
metabolized via the CYP450 pathway and is a weak inhibitor of CYP2D6 (De Martinis et al., 
2007; Liebowitz & Yeung, 2007; Septien- Velez et al., 2007). 
Duloxetine shows linear kinetics. The therapeutic dose range is 60-120 mg/day. Duloxetine 
has an elimination half-life of approximately 12.5 hours (range of 8 to 17 hours), and its 
pharmacokinetics are dose proportional over the therapeutic range. Steady-state is usually 
achieved after 3 days. Elimination of duloxetine is mainly through hepatic metabolism 
involving two P450 isozymes, CYP2D6 and CYP1A2 (Papakostas GI et al., 2007). 
 
Properties of SNRIs Venlafaxine Desvenlafaxine Duloxetine  Milnacipran Mirtazapine  
Therapeutic dose 
range 
75-375 
mg/day 
50 mg/day 60-120 
mg/day 
25-200 mg/day 15-45 mg/day 
Biotransformation CYP2D6 CYP3A4 CYP2D6, 
CYP1A2 
CYP2D6, 
CYP2C9 
CYP2D6,CYP3
A4,CYP1A2 
Half -life 4 h 9-10 h 12.5 h 12 h 20-40 h 
Elimination route renal renal renal, 
urine (72%), 
faeces (19%) 
renal Renal 
urine (75%), 
faeces (15 %) 
NE/5HT affinity ratio 15:7 13:8 9:3 2:1 - 
5HT/NE selectivity 30 3 x higher (NE 
binding) 
10 1 300 
Efficacy SNRI action 
is dose 
dependent 
Beter efficacy at 
low doses 
May require 
higher than 
the approved 
doses 
Beter efficacy 
at higher doses
Dose 
dependent 
Hepatic side effects Elevated 
liver 
enzymes 
- Complicated 
by alcohol 
consumption 
Elevated liver 
enzymes 
Hepatic 
insufficiency 
Cardiac side effects +  QTc interval 
prolongation 
- - - 
Sexual dysfunction Loss of 
libido, 
anorgasmia 
Delayed 
ejaculation 
Loss of libido, 
anorgasmia 
Decrease in 
sexual desire 
and ability 
Not cause 
significant 
sexual 
dysfunction 
Table 1. Quote from: Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin 
norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of 
their clinical efficacy. Hum Psychopharmacol. 2010 Jan;25(1):17-29. 
Milnacipran shows linear pharmacokinetics over a dose range of 25-200 mg/day. Milnacipran 
is rapidly and extensively absorbed and has a high bioavailability. Peak plasma concentrations 
are reached 2 hours after oral dosing. The elimination half-life is relatively short (12 hours) and 
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is increased by significant renal disease. Milnacipran is conjugated to an inactive glucuronide 
and excreted in the urine as an unchanged drug and conjugate. Enzymes of the CYP class do 
not play a role in the metabolism of this antidepressant drug so the risk of interactions with 
drugs metabolized by CYP enzymes is minimal (Puozzo & Panconi, 2002). 
Mirtazapine has an elimination half-life of 20-40 hours. Like most other antidepressants with 
a therapeutic-latency mirtazapine may require as long as 2–4 weeks for the therapeutic 
benefits of the drug to become evident. It is metabolized in the liver by the enzymes 
CYP2D6, CYP3A4 and CYP1A2. It does not have an active metabolite (Timmer &  Ad Sitsen,  
2000).  
3. Medical uses 
3.1 Efficacy and tolerability 
Depression is characterized by the presence of depressed mood and anhedonia (decreased 
pleasure or interest). It is also accompanied by a plethora of other signs and symptoms such 
as changes in appetite and sleeping, fatigue and loss of energy, psychomotor agitation or 
retardation, feelings of worthlessness or inappropriate guilt and diminished ability to think 
or concentrate (Bauer & Bschor, 2007). In general, antidepressants that are used today are 
effective in treating depression regardless of whether they primarly affect serotonergic or 
noradrenergic neurotransmission or both. It has been suggested that there may be 
differences in efficacy of antidepressants among certain patients. Evidence has 
demonstrated significantly greater remission rates with the SNRI venlafaxine compared 
with SSRIs (Bauer  et al., 2009). 
Evidence demonstrates that 5-HT and NA are involved in both the pathogenesis and 
recovery from depression. Preliminary results showed that dual acting antidepressants may 
have an advantage over single acting agents in terms of treating patients to remission. Dual 
acting agents may also be preferable for the treatment of chronic painful conditions and 
somatic symptoms (Sussman, 2003).  
Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, 
social phobia, panic disorder, and vasomotor symptoms. Venlafaxine inhibits the 
reuptake of both 5-HT and NA, thus combining two therapeutic mechanisms in one agent. 
The anticholinergic and cardiotoxic side effects are not as common compared with 
tricyclic antidepressants. Venlafaxine’s serotonergic actions are present at low doses, 
while its noradrenergic actions are progressively enhanced as the dose increases. 
Venlafaxine treatment stimulated expression of brain derived neurotrophic factor protein 
in the frontal cortex and inhibited long-term potentiation in the hippocampus (Cooke et 
al., 2009). 
Desvenlafaxine is a recently introduced antagonist of the human NE and 5HT transporters 
(hNET and hSERT) that is currently in clinical development for use in the treatment of major 
depressive disorder and vasomotor symptoms associated with menopause. Desvenlafaxine 
succinate is the succinate salt of the isolated major active metabolite of venlafaxine. 
Desvenlafaxine is being tested for the treatment of fibromyalgia with promising results 
(Wood, 2007). 
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Duloxetine is a newly developed tiophenpropanamin derivative. It is a SNRI indicated for 
the treatment of depression and for anxiety disorders but also approved for stress urinary 
incontinence, diabetic neuropathy and fibromyalgia. Duloxetine is approved for the 
treatment of major depressive disorder and diabetic peripheral neuropathic pain (Ormseth 
& Scholz, 2011). 
Milnacipran has a balanced activity on NA and 5-HT reuptake inhibition. Its efficacy in 
mild, moderate, and severe depression and suitable overall tolerability are combined with a 
low risk of causing pharmacokinetic drug-drug interactions, sexual dysfunction, changes in 
body weight in normal-weight patients, and toxicity due to overdose. This particular profile 
qualifies milnacipran as a first-line antidepressant for many depressed patients. Patients 
who have been withdrawn from SSRIs or other antidepressants due to lack of efficacy or 
intolerance may find milnacipran to be an effective therapeutic option. Also, milnacipran is 
an effective treatment option for patients with fibromyalgia. Current studies do not yet 
provide convincing evidence supporting the efficacy of mirtazapine, reboxetine, 
milnacipran and duloxetine for the treatment of panic disorder patients (Kasper et al., 2010; 
Serretti et al., 2010). 
Mirtazapine is a piridin analogue of mianserine. Mirtazapine is a newer antidepressant that 
exhibits both noradrenergic and serotonergic activity. It is a tetracyclic antidepressant used 
primarily in the treatment of major depressive disorder. It is unlike other agents used for 
depression both in its mechanism of action as well as its side effects.  It is at least as effective 
as the older antidepressants for treating mild to severe depression. Mirtazapine is relatively 
safe in overdose. Many clinicians consider mirtazapine a second-line or even third-line 
antidepressant to be used when older antidepressants are not tolerated or are ineffective. 
Physicians who are concerned about the risks of elevated lipid levels and agranulocytosis 
may choose to reserve mirtazapine as a third-line choice. It is particularly useful in patients 
who experience sexual side effects from other antidepressants. Mirtazapine is also a good 
choice in depressed patients with significant anxiety or insomnia. (Hartmann, 1999). It has 
been found to be useful in the treatment of generalized anxiety disorder, social anxiety 
disorder, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder 
(Benjamin & Doraiswamy, 2011). 
4. Studies with SNRIs in animal models 
Newer dual-acting antidepressants appear to possess analgesic effects similar to that of the 
TCAs but have a more favorable safety and tolerability profile. These drugs also may have 
an advantage over SSRIs in treating the painful physical symptoms of depression and in 
achieving remission of all symptoms of depression. Some animal models have been used to 
characterize the pathological conditions and the effects of drugs on these conditions. 
Researchers have compared the performance of SNRIs using novel animal models to 
evaluate the effects on depression, obsessive compulsive disorder, pain and learning and 
memory functions. 
4.1 Research via SNRIs and depression in animal models 
Antidepressants inhibiting the reuptake of both 5-HT and NA may exhibit efficacy superior 
to that of SSRIs. 
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Ulak et al. (2008) showed that the neuronal NOS inhibitor, 1-(2-trifluoromethylphenyl)-
imidazole, augments the effects of antidepressants acting via the serotonergic system in a 
forced swimming test (FST) in rats.  
The effects of subchronic treatment (24 days) with antidepressants displaying differential 
effects on NA and 5-HT reuptake on behavior, neurochemistry, and hypothalamic-pituitary-
adrenal (HPA) axis activity following FST exposure in the rat were studied. Desipramine 
significantly decreased immobility in the FST, while paroxetine and venlafaxine were 
without effect. Nonetheless, treatment with all three antidepressants significantly attenuated 
stress-related increases in amygdaloid and cortical serotonin turnover. Desipramine 
attenuated the stress-associated elevation in serum corticosterone. Connor and collegues 
(2000) concluded that although FST-induced increases in serotonin turnover in the frontal 
cortex and amygdala were attenuated following treatment with all three antidepressants, 
FST-induced behavioral changes and increased HPA axis activity were normalized only 
following desipramine treatment. 
The rat forced swimming test distinguishes between selective 5-HT and selective NA 
reuptake inhibitors, which increase swimming and climbing behaviors, respectively. Since 
adaptative neurochemical processes occur in the treatment of depression, the influence of 
long-term antidepressant treatment on these interactions was examined. Fluoxetine, 
desipramine, milnacipran and mirtazapine were administered subacutely and chronically. A 
subacute fluoxetine-desipramine combination was administered in rats that were pre-
treated with chronic-desipramine. NA system-mediated interactions were further examined 
by combining clonidine with fluoxetine. Results of this study showed that long-term 
treatment with either fluoxetine or desipramine did not modify the behavioral response 
produced by subacute administration. In contrast, whereas subacute-milnacipran increased 
climbing solely, chronic-milnacipran produced greater anti-immobility effects and increased 
both climbing and swimming behaviors. Similarly, the fluoxetine-desipramine combination 
produced climbing solely but increased both climbing and swimming behaviors in animals 
pre-treated with chronic desipramine. Chronic, but not subacute, mirtazapine increased 
swimming behavior. Clonidine dose-dependently antagonized fluoxetine-induced anti-
immobility effects and swimming behavior. It was concluded that chronic enhancement of 
NA transmission alters NA system-mediated inhibition of 5-HT-induced behavior in the 
FST, which may involve alpha (2)-receptors (Rénéric & Bouvard, 2002). 
Mochizuki D, et al. (2002) aimed to characterize, both neurochemically and behaviorally, the 
SNRI milnacipran in the prefrontal cortex in comparison with tricyclic antidepressants and 
selective serotonin reuptake inhibitors. It was concluded that milnacipran acts as an SNRI in 
vitro and in vivo and may be useful for the treatment of anxiety as well as depression 
(Mochizuki et al., 2002). 
Researchers aimed to investigate whether estrogen level changes in oviariectomized rats 
may lead to depression and memory disorders and whether the effects of such changes may 
be reversible following administration of venlafaxine using the Porsolt forced swimming 
test and Morris water maze test. It was reported that the regulatory role of estrogen and 
venlafaxine in antidepressant activity and memory function could be related to the 
interactions between noradrenergic and serotonergic systems (Nowakowska & Kus, 2005). 
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In another study, the relationship between the antidepressant effect of venlafaxine and its 
ability to protect animals against stress-induced oxidative lipid peroxidation and DNA 
damage was investigated. It was reported that long-term venlafaxine treatment using 
effective antidepressant doses can protect against stress-induced oxidative cellular and 
DNA damage. It was concluded that this action may occur by antagonizing oxidative stress 
and enhancing antioxidant defense mechanisms (Abdel-Wahab & Salama, 2011). 
In animal models detecting antidepressant activity, distinct NO synthase inhibitors 
displayed antidepressant-like action. Previous studies found that pretreatment with L-
arginine counteracted the antidepressant-like effect of imipramine and venlafaxine but not 
the effects of bupropion or fluoxetine. Increasing the dose of L-Arg to 1000 mg/kg 
attenuated the antidepressant-like effects of bupropion but did not modify the action of 
fluoxetine. L-Arginine was devoid of any locomotor effects on the animals. In that study, the 
idea that some antidepressants are able to inhibit nitric oxide synthesis in the brain, an effect 
that could be mechanistically related to the ability of L-arginine to counteract the 
antidepressant-like effects, was supported (Krass et al., 2011). 
Milnacipran was active in various animal models of depression, such as the forced 
swimming test in the mouse, learned helplessness in the rat and the olfactory bulbectomized 
rat model. Milnacipran represents an interesting new therapeutic option for depression 
being that it is as well tolerated as SSRIs but offers clinical efficacy similar to TCAs (Boyer & 
Briley, 1998).  
Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in 
the forced swimming test in mice were evaluated. It was found that MIR (2.5, 5 and 10 
mg/kg) and FLU (5 and 10 mg/kg) or risperidone in low doses (0.05 and 0.1 mg/kg) given 
alone did not change the immobility time of mice in the forced swimming test. Joint 
administration of MIR (5 and 10 mg/kg) or FLU (10 mg/kg) and risperidone (0.1 mg/kg) 
produced antidepressant-like activity in the forced swimming test (Rogóż  et al., 2010). 
The effect of venlafaxine, a dual reuptake inhibitor of 5-HT and NA, was evaluated in a 
murine model of chronic fatigue. It was concluded that daily treatment with venlafaxine for 
15 days produced a significant reduction in the immobility period and reversed various 
behavioral, biochemical and neurotransmitter alterations induced by chronic fatigue. 
Therefore, venlafaxine could be of therapeutic potential in the treatment of chronic fatigue 
(Dhir & Kulkarni, 2008). 
4.2 Research via SNRIs and anxiety and obsessive compulsive disorder in animal 
models  
The effects of milnacipran, a 5-HT and NA reuptake inhibitor (SNRI), on the obsessive 
compulsive disorder (OCD) model and marble burying behavior were investigated in mice. 
At doses above 10 mg/kg milnacipran inhibited marble burying behavior significantly in 
mice similar to fluvoxamine. Milnacipran doses inhibiting marble burying behavior did not 
affect locomotor activity. These results suggest that the inhibition of marble burying 
behavior may indicate that milnacipran may be useful for OCD therapy (Sugimoto et al., 
2007). 
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Milnacipran has not yet been systematically studied preclinically or clinically for the 
treatment of anxiety disorders. In the four-plate test (FPT) which is known to predict 
anxiolytic-like activity in mice, milnacipran demonstrated strong anti-punishment effects 
following acute administration. It was concluded that the activation of 5-HT2A receptors is 
critically involved in the anxiolytic activity of milnacipran (Bourin et al., 2005). 
Methods for detection of anxiolytic-like behavioral effects of serotonin uptake inhibitors are 
limited. Venlafaxine dose-dependently suppressed nestlet shredding and marble burying at 
doses that were generally without effect on rotorod performance. The amine-based 
antidepressant agents, imipramine and desipramine, as well as the selective NA transport 
inhibitor, nisoxetine, produced similar qualitative effects on these behaviors (Li & Morrow, 
2006). 
The effect of chronic treatment with venlafaxine on beta1 and 5-HT2 receptor populations 
was examined in the frontal cortex of olfactory bulbectomised (OB) and sham operated (SO) 
animals. The effect of these drugs on the behaviour of the animals on the elevated plus maze 
and the open field was also assessed. Removal of the bulbs resulted in a characteristic 
increase in locomotor activity in the OB animals in the open field which was reversed by 
chronic venlafaxine treatment. Venlafaxine produced a slight reduction in the number of 
open arm entries made by the OB animals although this failed to reach significance. A 
decrease in the affinity of beta1-adrenoceptors was found following olfactory bulbectomy 
and this was normalised by treatment with venlafaxine. Olfactory bulbectomy did not 
produce any changes in 5-HT2 receptor populations but venlafaxine administration 
significantly reduced the density of these receptors in both SO and OB animals. It was 
concluded that the usefulness of the OB as an animal model, for the detection of 
antidepressants from a wide variety of classes. (McGrath & Norman, 1998). The effect of 
acute treatment with seven antidepressants covering the classes selective serotonin reuptake 
inhibitors, serotonin–noradrenaline reuptake inhibitors, noradrenaline reuptake inhibitors 
and tricyclic antidepressants were compared with the benzodiazepine, chlordiazepoxide, on 
the mouse zero maze, an unconditioned model of anxiety. Duloxetine was anxiolytic after 
chronic but not acute treatment, reflecting clinical experience with antidepressants in 
general (Troelsen, 2005).  
Mirtazapine is an antidepressant with a unique mechanism of action and has been 
categorized as a noradrenergic and specific serotonergic antidepressant. Although 
numerous clinical trials suggested the usefulness of mirtazapine for not only major 
depressive disorders but also a variety of anxiety disorders, efficacy studies in animal 
anxiety models have been rarely reported. A potential anxiolytic-like profile of mirtazapine 
in rat conditioned fear stress model was investigated. It was reported that the anxiolytic-like 
action of mirtazapine involves activation of 5-HT1A receptor and alpha1 adrenoceptor to 
different extents, and are compatible with one aspect of mirtazapine's pharmacological 
profile (Kakui  et al., 2009). 
4.3 Research via SNRIs and learning-memory in animal models : 
Extensive evidence indicates that noradrenaline and serotonin modulate memory formation. 
In the literature there are a few works evaluating the effects of SNRIs on cognitive 
parameters such as learning, memory and habituation to novel environments. 
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Duloxetine, a potent inhibitor of 5-HT and noradrenaline reuptake with weak effects on 
dopamine reuptake, is used in the treatment of major depression. It has been recognized 
that some antidepressants can affect memory in humans, but there are no studies that report 
duloxetine effects on memory using the inhibitory avoidance method. A recent report 
investigated the effect of duloxetine on short- and long-term memory (STM and LTM) in the 
inhibitory avoidance task in mice. Duloxetine did not produce any effect on memory after 
acute and subacute administration, suggesting that this antidepressant does not affect either 
memory acquisition or consolidation (Pereira et al., 2009). 
The effects of milnacipran in animal models of anxiety and memory were evaluated via 
Vania K.M. Moojen and collegues, 2006; it was concluded that milnacipran can be useful in 
the treatment of anxiety disorders. The pharmacological characteristics of milnacipran, in 
modulation of the synaptic plasticity were investigated. It was found that Milnacipran, 
suppresses long-term potentiation in the rat hippocampal CA1 field via 5-HT1A receptors 
and a1-adrenoceptors (Tachibana  et al., 2004). It was reported that chronic treatment with 
milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear 
stress.  And it is concluded that anxiolytic mechanism(s) of chronic treatment with 
milnacipran may be explained by reversal effects on the psychological stress-induced 
impairment of synaptic plasticity (Matsumoto et al., 2004).  
Effect of venlafaxine on cognitive function and hippocampal brain-derived neurotrophic 
factor expression in rats with post-stroke depression were evaluated and it was reported 
that venlafaxine can improve post-stroke depression-induced learning and memory 
dysfunction, possibly through the enhancement of the BDNF level in the CA3 area of 
hippocampus. (Dai  &  Li , 2011).  
Ulak et al. (2006) reported that chronic administration of fluoxetine or venlafaxine induces 
memory deterioration in an inhibitory avoidance task in rats. In this study, the comparison 
of training latencies versus test latencies showed inhibition of passive avoidance learning in 
fluoxetine- or venlafaxine-treated rats (e.g., no significant difference between training and 
test latencies) in a step-through test. There was no significant difference between fluoxetine- 
and venlafaxine-induced reduction of latency in rats in this test. 
4.4 Research via SNRIs and pain in animal models 
5-HT and NA are implicated in modulating descending inhibitory pain pathways in the 
central nervous system. Duloxetine is a selective and potent dual 5-HT and NA reuptake 
inhibitor (SNRI). Iyengar  et al. (2004) reported that inhibition of both 5-HT and NA uptake 
may account for attenuation of persistent pain mechanisms. Thus, duloxetine may be useful 
in the treatment of human persistent and neuropathic pain states.  
Data from numerous animal and clinical studies suggest that dual acting antidepressants are 
more active in alleviating pain than specific NA reuptake inhibitors, which themselves are 
more potent than the SSRI (Fishbain, 2000 & Fishbain, 2000).  
Milnacipran, duloxetine and pregabalin (an ǂ2-δ1 Ca2+ channel blocker) are efficacious 
against fibromyalgia, a condition characterized by diffuse chronic pain and associated with 
stress. These compounds were compared in the study of Bardin et al. (2010) using rat 
models of acute/inflammatory pain and stress-induced ultrasonic vocalization. In the 
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formalin test, milnacipran dose-dependently attenuated paw elevation and licking. 
Duloxetine was slightly more potent. Pregabalin also reduced paw licking/late phase. 
Milnacipran dose-dependently reduced USV; duloxetine was less potent. Milnacipran, 
duloxetine and pregabalin possess analgesic activity in the formalin test on paw licking/late 
phase (corresponding to inflammatory pain with a central sensitization component). In the 
stress-induced USV model, milnacipran was the most potent and efficacious compound. To 
summarize, the reduction of formalin-induced paw licking/late phase might constitute a 
useful indicator of the potential activity against inflammatory/centrally sensitized pain, as 
might be expressed in fibromyalgia (Bardin et al., 2010).  
Milnacipran has shown efficacy against several chronic pain conditions including 
fibromyalgia. A previous report evaluated its anti-allodynic effects following acute or sub-
chronic treatment in a rat model of neuropathic pain (chronic constriction injury (CCI) of the 
sciatic nerve). It is reported that milnacipran is as efficacious as the reference compound 
amitriptyline in a pre-clinical model of injury-induced neuropathy and demonstrates, for the 
first time, that it is active acutely and sub-chronically against cold allodynia. It is also 
suggested that milnacipran has the potential to alleviate allodynia associated with nerve 
compression-induced neuropathic pain in the clinic (for example, following discal hernia, 
avulsion or cancer-induced tissue damage) (Berrocoso et al., 2011). 
5. Side effects  
Sexual dysfunction is often a side effect of drugs that inhibit 5-HT reuptake in general. 
Specifically, common side effects with venlafaxine include difficulty becoming aroused, lack 
of interest in sex, and anorgasmia. Genital anesthesia, loss of or decreased response to 
sexual stimuli, and ejaculatory anhedonia are also possible. Other side effects include 
nausea, somnolence, dry mouth, dizziness, insomnia, constipation and yawn. With 
desvenlafaxine nausea was consistently the most common complaint and the most common 
reason for discontinuation. Less common mild side effects, but more serious, adverse effects 
reported includes hypertension, QTc interval prolongation, exacerbation of ischemic cardiac 
disease, elevated lipids and elevated liver enzymes (Sproule BA and Hazra M, 2008). 
Nausea, somnolence, insomnia, and dizziness were the main side effects reported by 
approximately 10% to 20% of patients using duloxetine. In a trial for mild major depressive 
disorder (MDD), the most commonly reported treatment-emergent adverse events among 
duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and 
dizziness (18.7%), and except for headache, these were reported significantly more often 
than the placebo group. Duloxetine and SSRIs have been shown to cause sexual side effects 
in some patients, including both males and females. (Bitter &  Filipovits, 2011). 
Common side effects of mirtazapine included dizziness, blurred vision, sedation, 
somnolence, malaise/lassitude, increased appetite and subsequent weight gain, dry mouth, 
constipation, vivid, bizarre, lucid dreams or nightmares, joint pain (arthralgia), muscle pain 
(myalgia) and back pain. Less common side effects included agitation/restlessness, 
irritability, aggression, apathy and/or anhedonia (i.e., inability to experience pleasurable 
emotions), loss of interest in previously enjoyed activities, excessive mellowness or 
calmness, difficulty swallowing, shallow breathing, decreased body temperature, miosis, 
nocturnal emissions, spontaneous orgasm, loss of balance, and restless legs syndrome. 
Mirtazapine has a lower risk of many of the side effects encountered with other 
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antidepressants, such as decreased appetite, insomnia, nausea and vomiting, diarrhea, 
urinary retention, increased body temperature, increased perspiration/sweating, mydriasis, 
and sexual dysfunction (consisting of loss of libido and anorgasmia). Sedation is the most 
common side effect of mirtazapine. Although agranulocytosis is the most serious side effect, 
it is rare (approximately one in 1,000) and usually reversible when the medication is 
stopped. In general, some antidepressants may have the capacity to exacerbate some 
patients' depression or anxiety or cause suicidal ideation, particularly early in the treatment. 
It has been proven that mirtazapine has a faster onset of antidepressant action compared to 
SSRIs (Hartmann, 1999). 
With milnacipran the most frequently occurring adverse reactions were nausea, headache, 
constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate 
increase, dry mouth, and hypertension. Milnacipran can have a significant impact on sexual 
function, including both a decrease in sexual desire and ability. Milnacipran can cause pain 
and swelling of the testicles in men as well as blood in the urine and stools. The incidence of 
cardiovascular and anticholinergic side effects was significantly lower compared with TCAs 
in a controlled study with over 3,300 patients. Elevation of liver enzymes without signs of 
symptomatic liver disease has been infrequent. Mood swing to mania has also been 
observed and dictates termination of treatment. In psychotic patients, emergence of delirium 
has been noticed. Milnacipran has a low incidence of sedation but improves sleep (both 
duration and quality) in depressed patients. In agitated patients or those with suicidal 
thoughts, additive sedative/anxiolytic treatment is usually indicated (Nakagowa et al., 2009; 
Montgomery et al., 1996). 
6. Conclusion 
In this chapter of antidepressants including the SNRIs, pharmacology, medical uses, 
tolerability, experimental studies and side effects of SNRIs are overviewed. They include 
venlafaxine, desvenlafaxine, duloxetine, milnacipran and mirtazapine. Pharmacology of 
SNRIs is characterized by the inhibition of both serotonin and noradrenaline at the 
presynaptic membrane and by weak affinity with receptors at the postsynaptic membrane, 
which expects well efficacy on major depressive disorder with less adverse effects in clinical 
use. SNRIs are well tolerated in general. SNRIs can be considered to be the first-line 
antidepressant drugs. 
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